Skip to main content
SpringerLink
Log in

Preventive Therapy Against Tuberculosis

  • Chapter
  • First Online:
Handbook of Global Tuberculosis Control

  • 906 Accesses

Abstract

The drug of choice for tuberculosis (TB) preventive therapy is isoniazid (INH). Preventive therapy can reduce TB incidence up to 60 %. In those infected with HIV, where the risk of progression from infection to active TB disease is 20–37 times higher, INH has proven effective in preventing TB disease. The priority populations for preventive therapy are the HIV positive and children younger than 5 years old who have household close contact with smear-positive TB patients. The main challenges with preventive therapy are adverse drug reactions and compliance issues. TB preventive therapy has become an important TB control strategy in many high-income countries. The high cost, poor acceptability, and difficulties in treatment management limit the application of preventive therapy in low-income countries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akolo, C., Adetifa, I., Shepperd, S., & Volmink, J. (2010). Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews, 1, CD000171.

    Google Scholar 

  • American Thoracic Society. (1986). American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. The American Review of Respiratory Disease, 134(2), 355–363.

    Google Scholar 

  • American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. (2003). American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167(4), 603–662.

    Article  Google Scholar 

  • Camins, B. C., Bock, N., Watkins, D. L., & Blumberg, H. M. (1996). Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion. JAMA, 275(13), 1013–1015.

    Article  CAS  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention (CDC). (1996). The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 45(RR-4), 1–18.

    Google Scholar 

  • Centers for Disease Control and Prevention (CDC). (2001). Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. Morbidity and Mortality Weekly Report, 50(15), 289–291.

    Google Scholar 

  • Centers for Disease Control and Prevention (CDC). (2010). Latent tuberculosis infection: A guide for primary health care providers. Atlanta: Centers for Disease Control and Prevention. Updated version. Retrieved Mar 4, 2015, from http://www.cdc.gov/tb/publications/ltbi/pdf/targetedltbi.pdf

  • Cohn, D. L., O’Brien, R. J., Geiter, L. J., Gordin, F. M., Hershfield, E., Horsburgh, C. R., et al. (2000). Targeted tuberculin testing and treatment of latent tuberculosis infection. Morbidity and Mortality Weekly Report, 49(6), 1–54.

    Google Scholar 

  • Comstock, G. W. (1999). How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? [Counterpoint]. The International Journal of Tuberculosis and Lung Disease, 3(10), 847–850.

    CAS  PubMed  Google Scholar 

  • Comstock, G. W., Ferebee, S. H., & Hammes, L. M. (1967). A controlled trial of community-wide isoniazid prophylaxis in Alaska. The American Review of Respiratory Disease, 95(6), 935–943.

    CAS  PubMed  Google Scholar 

  • Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., et al. (2003). The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 163(9), 1009–1021.

    Article  PubMed  Google Scholar 

  • Egsmose, T., Ang’Awa, J. O. W., & Poti, S. J. (1965). The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bulletin of the World Health Organization, 33(3), 419–433.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ena, J., & Valls, V. (2005). Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis. Clinical Infectious Diseases, 40(5), 670–676.

    Article  CAS  PubMed  Google Scholar 

  • Ferebee, S. H. (1970). Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibliotheca Tuberculosea, 26, 28–106.

    CAS  PubMed  Google Scholar 

  • Ferebee, S. H., & Mount, F. W. (1962). Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. American Review of Respiratory Disease, 85, 490–510.

    CAS  PubMed  Google Scholar 

  • Ferebee, S. H., Mount, F. W., Murray, F. J., & Livesay, V. T. (1963). A controlled trial of isoniazid prophylaxis in mental institutions. American Review of Respiratory Disease, 88, 161–175.

    CAS  PubMed  Google Scholar 

  • Gao, S. Y., Zhang, G. R., Ma, S. W., Wang, G. J., & Wang, Y. Y. (2004). Study on treatment effects of rifapentine preventing tuberculosis for positive PPD reaction. Henan Medical Research, 13(4), 347–350.

    Google Scholar 

  • Gao, X. F., Wang, L., Liu, G. J., Wen, J., Sun, X., Xie, Y., et al. (2006). Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: A meta-analysis [Review Article]. The International Journal of Tuberculosis and Lung Disease, 10(10), 1080–1090.

    CAS  PubMed  Google Scholar 

  • Garibaldi, R. A., Drusin, R. E., Ferebee, S. H., & Gregg, M. B. (1972). Isoniazid-associated hepatitis. Report of an outbreak. The American Review of Respiratory Disease, 106(3), 357–365.

    Article  CAS  PubMed  Google Scholar 

  • Getahun, H., Gunneberg, C., Granich, R., & Nunn, P. (2010). HIV infection—Associated tuberculosis: The epidemiology and the response. Clinical Infectious Diseases, 50(Suppl. 3), S201–S207.

    Article  PubMed  Google Scholar 

  • Girling, D. J. (1982). Adverse effects of antituberculosis drugs. Drugs, 23(1–2), 56–74.

    Article  CAS  PubMed  Google Scholar 

  • Goldman, A. L., & Braman, S. S. (1972). Isoniazid: A review with emphasis on adverse effects. Chest, 62(1), 71–77.

    Article  CAS  PubMed  Google Scholar 

  • Gordin, F., Chaisson, R. E., Matts, J. P., Miller, C., de Lourdes Garcia, M., Hafner, R., et al. (2000). Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial. JAMA, 283(11), 1445–1450.

    Article  CAS  PubMed  Google Scholar 

  • Heal, G., Elwood, R. K., & FitzGerald, J. M. (1998). Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia. The International Journal of Tuberculosis and Lung Disease, 2(12), 979–983.

    CAS  PubMed  Google Scholar 

  • Holscher, C. G. B. (1968). Secondary chemoprophylaxis with isonicotinic acid hydrazide. Dissertation. Summary. Retrieved from http://irs.ub.rug.nl/ppn/82224621X

  • Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. (1992). A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. American Review of Respiratory Disease, 145(1), 36–41.

    Article  Google Scholar 

  • Horsburgh, C. R., Jr., & Rubin, E. J. (2011). Latent tuberculosis infection in the United States. New England Journal of Medicine, 364(15), 1441–1448.

    Article  CAS  PubMed  Google Scholar 

  • Horsburgh, C. R., Jr., Goldberg, S., Bethel, J., Chen, S., Colson, P. W., Hirsch-Moverman, Y., et al. (2010). Latent TB infection treatment acceptance and completion in the United States and Canada. Chest, 137(2), 401–409.

    Article  PubMed  Google Scholar 

  • Horwitz, O., Payne, P. G., & Wilbek, E. (1966). Epidemiological basis of tuberculosis eradication: 4. The isoniazid trial in Greenland. Bulletin of the World Health Organization, 35(4), 509–526.

    CAS  PubMed  PubMed Central  Google Scholar 

  • International Union Against Tuberculosis Committee on Prophylaxis. (1982). Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bulletin of the World Health Organization, 60(4), 555–564.

    PubMed Central  Google Scholar 

  • Jasmer, R. M., Snyder, D. C., Chin, D. P., Hopewell, P. C., Cuthbert, S. S., Paz, E. A., et al. (2000). Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: An outcome and cost-effectiveness analysis. American Journal of Respiratory and Critical Care Medicine, 162(5), 1648–1652.

    Article  CAS  PubMed  Google Scholar 

  • Konstantinos, A. (2010). Testing for tuberculosis. Australian Prescriber, 33(1), 12–18.

    Article  Google Scholar 

  • Kopanoff, D. E., Snider, D. E., Jr., & Caras, G. J. (1978). Isoniazid-related hepatitis: A US Public Health Service cooperative surveillance study. The American Review of Respiratory Disease, 117(6), 991–1001.

    CAS  PubMed  Google Scholar 

  • Lardizabal, A., Passannante, M., Kojakali, F., Hayden, C., & Reichman, L. B. (2006). Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest, 130(6), 1712–1717.

    Article  CAS  PubMed  Google Scholar 

  • Lecoeur, H. F., Truffot-Pernot, C., & Grosset, J. H. (1989). Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. American Journal of Respiratory and Critical Care Medicine, 140(5), 1189–1193.

    CAS  Google Scholar 

  • Lobue, P., & Menzies, D. (2010). Treatment of latent tuberculosis infection: An update. Respirology, 15(4), 603–622.

    Article  PubMed  Google Scholar 

  • LoBue, P. A., & Moser, K. S. (2003). Use of isoniazid for latent tuberculosis infection in a public health clinic. American Journal of Respiratory and Critical Care Medicine, 168(4), 443–447.

    Article  PubMed  Google Scholar 

  • Long, R., & Ellis, E. (Eds.). (2007). Canadian tuberculosis standards (6th ed.). Ottawa: Public Health Agency of Canada. Retrieved Mar 4, 2015, from http://csao.net/files/pdfs/Canadian%20Tuberculois%20Standards%202007%206th%20edition.pdf

  • Manabe, Y. C., & Bishai, W. R. (2000). Latent Mycobacterium tuberculosis—persistence, patience, and winning by waiting. Nature Medicine, 6(12), 1327–1329.

    Google Scholar 

  • McNab, B. D., Marciniuk, D. D., Alvi, R. A., Tan, L., & Hoeppner, V. H. (2000). Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines. American Journal of Respiratory and Critical Care Medicine, 162(3), 989–993.

    Article  CAS  PubMed  Google Scholar 

  • Menzies, D., Dion, M. J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K. (2004). Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. American Journal of Respiratory and Critical Care Medicine, 170(4), 445–449.

    Article  PubMed  Google Scholar 

  • Monaco, A. (1964). Antituberculous chemoprophylaxis in silicotics. Bulletin of the International Union against Tuberculosis, 35, 51–56.

    CAS  PubMed  Google Scholar 

  • Mount, F. W., & Ferebee, S. H. (1962). The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. American Review of Respiratory Disease, 85, 821.

    CAS  PubMed  Google Scholar 

  • Mwinga, A., Hosp, M., Godfrey-Faussett, P., Quigley, M., Mwaba, P., Mugala, B. N., et al. (1998). Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS, 12(18), 2447–2457.

    Article  CAS  PubMed  Google Scholar 

  • Page, K. R., Sifakis, F., Montes de Oca, R., Cronin, W. A., Doherty, M. C., Federline, L., et al. (2006). Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: A retrospective study. Archives of Internal Medicine, 166(17), 1863–1870.

    Article  CAS  PubMed  Google Scholar 

  • Pape, J. W., Jean, S. S., Ho, J. L., Hafner, A., & Johnson, W. D. (1993). Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. The Lancet, 342(8866), 268–272.

    Article  CAS  Google Scholar 

  • Riley, L. W. (1993). Drug resistant tuberculosis. Clinical Infectious Diseases, 17(Suppl. 2), S442–S446.

    Article  PubMed  Google Scholar 

  • Runyon, E. H. (1965). Preventive treatment in tuberculosis: A statement by the Committee on Therapy, American Thoracic Society. American Review of Respiratory Disease, 91, 297–298.

    CAS  PubMed  Google Scholar 

  • Salpeter, S. R. (1993). Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. Western Journal of Medicine, 159(5), 560–564.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Schechter, M., Zajdenverg, R., Falco, G., Barnes, G. L., Faulhaber, J. C., Coberly, J. S., et al. (2006). Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. American Journal of Respiratory and Critical Care Medicine, 173(8), 922–926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Snider, D. E., Jr., & Caras, G. J. (1992). Isoniazid-associated hepatitis deaths: A review of available information. The American Review of Respiratory Disease, 145(2 Pt 1), 494–497.

    Article  PubMed  Google Scholar 

  • Snider, D. E., Jr., Caras, G. J., & Koplan, J. P. (1986). Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy. JAMA, 255(12), 1579–1583.

    Article  PubMed  Google Scholar 

  • Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 99(2), 465–471.

    Article  CAS  PubMed  Google Scholar 

  • Sterling, T. R., Bethel, J., Goldberg, S., Weinfurter, P., Yun, L., & Horsburgh, C. R. (2006). The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. American Journal of Respiratory and Critical Care Medicine, 173(8), 927–931.

    Article  PubMed  Google Scholar 

  • Tu, D. H. (2005). TB preventive therapy. Chinese Journal of Clinical Drug Therapy, 3(2), 32–34.

    Google Scholar 

  • Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., et al. (1997). A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. New England Journal of Medicine, 337(12), 801–808.

    Article  CAS  PubMed  Google Scholar 

  • White, M., Gournis, E., Kawamura, M., Menendez, E., & Tulsky, J. (2003). Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco. The International Journal of Tuberculosis and Lung Disease, 7(1), 30–35.

    CAS  PubMed  Google Scholar 

  • WHO. (2011). Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization.

    Google Scholar 

  • Ziakas, P. D., & Mylonakis, E. (2009). 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: A meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clinical Infectious Diseases, 49(12), 1883–1889.

    Article  PubMed  Google Scholar 

  • Ziv, E., Daley, C. L., & Blower, S. M. (2001). Early therapy for latent tuberculosis infection. American Journal of Epidemiology, 153(4), 381–385.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155 Changbai Road, Changping District, Beijing, China

    Lin Zhou & Eryong Liu

Authors
  1. Lin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eryong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lin Zhou .

Editor information

Editors and Affiliations

  1. Haikou VTI Biological Institute, Boston, Massachusetts, USA

    Yichen Lu

  2. Chinese Nat’l Ctr Disease Control and Prevention, Nat’l Center for TB Control & Prevention Chinese Nat’l Ctr Disease Control and Prevention, Beijing, China

    Lixia Wang

  3. National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

    Hongjin Duanmu

  4. Brookline, Massachusetts, USA

    Chris Chanyasulkit

  5. Vaccine Technologies, Inc., Wellesley, Massachusetts, USA

    Amie J. Strong

  6. National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

    Hui Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Zhou, L., Liu, E. (2017). Preventive Therapy Against Tuberculosis. In: Lu, Y., Wang, L., Duanmu, H., Chanyasulkit, C., Strong, A., Zhang, H. (eds) Handbook of Global Tuberculosis Control. Springer, Boston, MA. https://doi.org/10.1007/978-1-4939-6667-7_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6667-7_23

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4939-6665-3

  • Online ISBN: 978-1-4939-6667-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation